MK 0429

Drug Profile

MK 0429

Alternative Names: MK 0429; MK-429

Latest Information Update: 23 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 03 Oct 2007 Data presented at the American Society for Bone and Mineral Research 29th Annual Meeting (ASBMR-2007) added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
  • 31 Mar 2006 Phase-I clinical trials in Prostate cancer in France (PO)
  • 31 Mar 2006 Phase-I clinical trials in Prostate cancer in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top